辛伐他汀联合艾司西酞普兰治疗抑郁症合并肥胖的随机临床试验
该研究为在德国9个三级医疗中心开展的双盲、安慰剂对照、多中心随机临床试验,纳入161例抑郁症合并肥胖的成人患者,比较辛伐他汀(40 mg/日)或安慰剂联合艾司西酞普兰治疗12周的疗效。结果显示,辛伐他汀组与安慰剂组的MADRS评分变化无显著差异,但辛伐他汀显著改善了低密度脂蛋白胆固醇、总胆固醇和C反应蛋白等心血管风险指标。
要点
- 辛伐他汀联合艾司西酞普兰未显著改善抑郁症合并肥胖患者的抑郁症状。
- 辛伐他汀显著降低了低密度脂蛋白胆固醇、总胆固醇和C反应蛋白水平。
- 研究未达到主要终点,不支持辛伐他汀作为抑郁症合并肥胖的增效治疗。
核心结论
- 在抑郁症合并肥胖患者中,辛伐他汀联合艾司西酞普兰治疗12周未产生额外的抗抑郁效果,尽管改善了心血管风险指标。
研究设计与样本
- 确证性、双盲、安慰剂对照、多中心随机临床试验,在德国9个三级医疗中心开展,纳入161例抑郁症合并肥胖的成人患者,160例纳入意向性治疗分析(安慰剂组79例,辛伐他汀组81例)。
主要发现
- 辛伐他汀组在心理健康相关次要终点上均未观察到显著效果。
关键数值与推荐
- 辛伐他汀40 mg/日联合艾司西酞普兰(前2周10 mg,之后增至20 mg)治疗12周。
- 研究保留率95.6%,盲法有效维持,严重不良事件4例且组间无差异。
临床怎么用
- 对于抑郁症合并肥胖的患者,不应将辛伐他汀作为艾司西酞普兰的常规增效治疗以改善抑郁症状。
- 辛伐他汀可用于改善该类患者的心血管风险指标,如降低低密度脂蛋白胆固醇、总胆固醇和C反应蛋白。
局限性
- 研究未达到主要终点,样本量有限(160例纳入意向性治疗分析),仅涉及德国9个三级医疗中心,随访12周,可能限制结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Major depressive disorder (MDD) and obesity are common noncommunicable disorders associated with substantial disease burden, which frequently occur comorbidly. Intriguingly, converging lines of evidence from animal models and genetic and observational studies have suggested a biological link between obesity, metabolic syndrome, and depression. Several small randomized clinical trials (RCTs) have suggested the antidepressive potential of statins. OBJECTIVE: To examine whether simvastatin added to escitalopram is efficacious in improving depressive symptoms compared with add-on placebo. DESIGN, SETTING, AND PARTICIPANTS: This was a confirmatory, double-blind, placebo-controlled, multicenter RCT. Adults with MDD and comorbid obesity from 9 tertiary care settings in Germany were enrolled in this analysis. Data were analyzed from July to October 2024. INTERVENTIONS: Simvastatin (40 mg per day) or placebo as add-on to escitalopram (10 mg for the first 2 weeks, then increased to 20 mg until the end of study) in a double-blind fashion for 12 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline (week 0) to week 12. RESULTS: From August 21, 2020, to June 06, 2024, a total of 161 patients were enrolled at 9 sites in Germany, of which 160 patients were included in the intention-to-treat analysis (placebo: n = 79, simvastatin: n = 81; mean [SD] age, 39.0 [11.0] years; 126 female [79%]). Retention in the trial was excellent (95.6%), and blinding was effectively maintained. There were 4 serious adverse events with no difference between the groups. Primary end point analysis in the intention-to-treat sample showed no significant treatment effect of add-on simvastatin in MADRS scores (mixed models for repeated measures least squares mean difference, 0.47 points; 95% CI, -2.08 to 3.02; P = .71). No effects of simvastatin treatment were observed in any of the mental health-related secondary end points. However, simvastatin treatment significantly reduced low-density lipoprotein cholesterol (simvastatin, -40.37 mg/dL; 95% CI, -47.41 to -33.33 mg/dL; placebo, -3.78 mg/dL; 95% CI, -11.18 to 3.62 mg/dL; P < .001), total cholesterol (simvastatin, -39.07 mg/dL; 95% CI, -49.42 to -28.73 mg/dL; placebo, -4.89 mg/dL; 95% CI, -15.64 to 5.87 mg/dL; P < .001), and C-reactive protein (simvastatin, -1.04 mg/L; 95% CI, -1.89 to -0.20 mg/L; placebo, 0.57 mg/L; 95% CI, -0.28 to 1.42 mg/L; P = .003) compared with placebo. CONCLUSIONS AND RELEVANCE: The study failed to meet its primary end point. This demonstrates that simvastatin did not exert additional antidepressive effects when added to escitalopram in patients with comorbid MDD and obesity, despite improving the cardiovascular risk profile. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04301271.
引用
- Otte C, Chae WR, Dogan DY, et al. Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 40465256. doi:10.1001/jamapsychiatry.2025.0801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。